• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

平台临床试验的效率:对未来的展望。

Efficiencies of platform clinical trials: A vision of the future.

作者信息

Saville Benjamin R, Berry Scott M

机构信息

Berry Consultants, Austin, TX, USA Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA

Berry Consultants, Austin, TX, USA Adjunct faculty, University of Kansas Medical Center, Department of Biostatistics, KS, USA.

出版信息

Clin Trials. 2016 Jun;13(3):358-66. doi: 10.1177/1740774515626362. Epub 2016 Feb 17.

DOI:10.1177/1740774515626362
PMID:26908536
Abstract

BACKGROUND

A "platform trial" is a clinical trial with a single master protocol in which multiple treatments are evaluated simultaneously. Adaptive platform designs offer flexible features such as dropping treatments for futility, declaring one or more treatments superior, or adding new treatments to be tested during the course of a trial.

METHODS

A simulation study explores the efficiencies of various platform trial designs relative to a traditional two-arm strategy.

RESULTS

Platform trials can find beneficial treatments with fewer patients, fewer patient failures, less time, and with greater probability of success than a traditional two-arm strategy.

CONCLUSION

In an era of personalized medicine, platform trials provide the innovation needed to efficiently evaluate modern treatments.

摘要

背景

“平台试验”是一种采用单一主方案的临床试验,其中可同时评估多种治疗方法。适应性平台设计具有灵活的特点,例如因无效而放弃某些治疗方法、宣布一种或多种治疗方法更优,或者在试验过程中增加新的待测试治疗方法。

方法

一项模拟研究探讨了各种平台试验设计相对于传统双臂策略的效率。

结果

与传统双臂策略相比,平台试验能够以更少的患者、更少的患者失败、更短的时间以及更高的成功概率找到有益的治疗方法。

结论

在个性化医疗时代,平台试验提供了有效评估现代治疗方法所需的创新。

相似文献

1
Efficiencies of platform clinical trials: A vision of the future.平台临床试验的效率:对未来的展望。
Clin Trials. 2016 Jun;13(3):358-66. doi: 10.1177/1740774515626362. Epub 2016 Feb 17.
2
Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.平台临床试验中多臂多阶段设计与适应性随机化的比较。
Contemp Clin Trials. 2017 Mar;54:48-59. doi: 10.1016/j.cct.2017.01.003. Epub 2017 Jan 13.
3
Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.贝叶斯自适应设计在多臂试验中的应用:骨科案例研究。
Trials. 2020 Jan 14;21(1):83. doi: 10.1186/s13063-019-4021-0.
4
A simulation study of outcome adaptive randomization in multi-arm clinical trials.多臂临床试验中结局自适应随机化的模拟研究。
Clin Trials. 2017 Oct;14(5):432-440. doi: 10.1177/1740774517692302. Epub 2017 Feb 1.
5
A Bayesian response-adaptive trial in tuberculosis: The endTB trial.一项结核病的贝叶斯反应适应性试验:终结结核病试验。
Clin Trials. 2017 Feb;14(1):17-28. doi: 10.1177/1740774516665090. Epub 2016 Sep 23.
6
Borrowing Concurrent Information from Non-Concurrent Control to Enhance Statistical Efficiency in Platform Trials.从非同期对照中借用同期信息以提高平台试验的统计效率。
Curr Oncol. 2023 Mar 31;30(4):3964-3973. doi: 10.3390/curroncol30040300.
7
ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage.ComPAS:一种具有自适应收缩的贝叶斯药物联合平台试验设计。
Stat Med. 2019 Mar 30;38(7):1120-1134. doi: 10.1002/sim.8026. Epub 2018 Nov 12.
8
MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.MIDAS:一种针对使用分子靶向药物的平台试验的实用贝叶斯设计方法。
Stat Med. 2016 Sep 30;35(22):3892-906. doi: 10.1002/sim.6971. Epub 2016 Apr 25.
9
Designing a Bayesian adaptive clinical trial to evaluate novel mechanical ventilation strategies in acute respiratory failure using integrated nested Laplace approximations.设计一项贝叶斯自适应临床试验,使用集成嵌套拉普拉斯逼近法评估急性呼吸衰竭中新型机械通气策略。
Contemp Clin Trials. 2024 Jul;142:107560. doi: 10.1016/j.cct.2024.107560. Epub 2024 May 10.
10
Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.多臂临床试验中的适应性治疗分配和选择:贝叶斯视角。
BMC Med Res Methodol. 2022 Feb 20;22(1):50. doi: 10.1186/s12874-022-01526-8.

引用本文的文献

1
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations: statistical elements and design.为免疫功能低下人群制定优化的COVID-19疫苗接种计划:统计要素与设计
Trials. 2025 Jul 25;26(1):256. doi: 10.1186/s13063-025-08965-w.
2
Platform trials-an emerging methodology for perioperative medicine: a narrative review.平台试验——围手术期医学的一种新兴方法:一篇叙述性综述
Perioper Med (Lond). 2025 Jul 4;14(1):67. doi: 10.1186/s13741-025-00543-7.
3
Platform trials: key features, when to use them and methodological challenges.
平台试验:关键特征、何时使用以及方法学挑战。
Med J Aust. 2025 Aug 4;223(3):120-122. doi: 10.5694/mja2.52711. Epub 2025 Jun 22.
4
Statistical Modeling to Adjust for Time Trends in Adaptive Platform Trials Utilizing Non-Concurrent Controls.利用非同期对照对适应性平台试验中的时间趋势进行调整的统计建模。
Biom J. 2025 Jun;67(3):e70059. doi: 10.1002/bimj.70059.
5
Lessons from the PROTECT-CH COVID-19 platform trial in care homes.来自护理院PROTECT-CH COVID-19平台试验的经验教训。
Health Technol Assess. 2025 Apr 9:1-26. doi: 10.3310/MTRS8833.
6
Democratising clinical trials research to strengthen primary health care.使临床试验研究民主化以加强初级卫生保健。
Lancet Glob Health. 2025 Apr;13(4):e749-e758. doi: 10.1016/S2214-109X(24)00513-8.
7
INCEPT: The Intensive Care Platform Trial-Design and protocol.INCEPT:重症监护平台试验——设计与方案
Acta Anaesthesiol Scand. 2025 Apr;69(4):e70023. doi: 10.1111/aas.70023.
8
Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives.肿瘤非特异性疗法的实践:挑战、创新与未来展望
Cancers (Basel). 2025 Feb 26;17(5):801. doi: 10.3390/cancers17050801.
9
Operating characteristics of unequal allocation ratios in platform trials with the staggered addition of drugs using binary endpoints.在使用二元终点指标且药物逐步添加的平台试验中,不等分配比的操作特征。
Contemp Clin Trials Commun. 2025 Feb 17;44:101450. doi: 10.1016/j.conctc.2025.101450. eCollection 2025 Apr.
10
Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial.多疾病、多领域平台试验的统计文档:我们在金黄色葡萄球菌网络适应性平台试验中的经验
Trials. 2025 Feb 11;26(1):49. doi: 10.1186/s13063-024-08684-8.